Skip to main content
Premium Trial:

Request an Annual Quote

Sequencing Technology Developer Omniome Raises $60M in Series B

NEW YORK (GenomeWeb) – Omniome, which his developing a new DNA sequencing technology, has raised $60 million in a Series B financing round, the company said today.

The round was led by Decheng Capital and Hillhouse Capital. They were joined by new investors Lam Research Capital and Nan Fung Life Sciences and by current investors ARCH Venture Partners, Domain Associates, Biomatics Capital Partners, and Altitude Life Science Ventures.

The San Diego-based company is developing a new sequencing platform that relies on so-called Sequencing By Binding technology and promises to provide highly accurate and fast results at low cost.

Omniome plans to use the proceeds in part to hire staff in several areas, particularly engineering, and to increase its research and production capacity.  It will continue to optimize its technology and accelerate prototype development.

Dave Mullarkey, the company's president and CEO, said in a statement that Omniome has validated its sequencing biochemistry. "Now we are directing our efforts on product development to rapidly advance our first commercial instrument prototypes." He is the former president and chief operating officer of Ariosa Diagnostics.

The Scan

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.

Vitamin D From Tomatoes

According to Reuters, researchers in the UK have gene-edited tomatoes so their fruit contains vitamin D.

Cause Not Yet Spotted

NPR reports that a new study was unable to find a cause for persistent long COVID symptoms.

PNAS Papers on Central African Hunter-Gatherers, Myopia Development, Ancient Microtia Allele

In PNAS this week: population patterns among Central African hunter gatherers, effect of myopia-linked gene variant, and more.